Hosted on MSN3mon
Acrux scores fourth FDA approval, Nitroglycerin Ointment moving into commercialisationThe ointment is a generic version of Rectiv and will be entering a market in which annual sales for the branded product and another generic competitor have exceeded US$23 million for the sale of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results